SURAKSHA Suraksha Diagnostic Q4 FY25 results (Jan–Mar 2025) and concall
Management summary
- Suraksha Diagnostic Limited delivered a strong FY25 with 15% revenue growth and 16% EBITDA growth, maintaining healthy 34% margins.
- The company expanded its network to 55 centers and strategically acquired Fetomat Wellness to enhance its fetal medicine offerings.
- Despite Q4 EBITDA being impacted by one-time costs and operational headwinds, management is optimistic about FY26, guiding for 18-20% revenue growth and 36% EBITDA margins.
- Continued network expansion and stabilization of newer centers..
Source: Inve concall analysis and management guidance record.
Highlights
-
FY25 Total Income grew 15% year-on-year to ₹255.94 crores.
-
FY25 EBITDA registered a healthy growth of 16% to ₹85.09 crores, with margins maintained at approximately 34%.
-
FY25 PAT increased by 34% to ₹30.98 crores, improving PAT margin to 12.3% from 10.6% in FY24.
-
Successfully expanded network by adding 7 new centers in FY25, bringing the total to 55 centers as of March 2025.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 59 | 64 |
| EBITDA | 18 | 20 |
| Net profit | 6 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Revenue Growth Revenue · FY26 · High confidence 18%-20%
Profitability
EBITDA Margin Profitability · FY26 · High confidence ~36%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2One-off costs impacting Q4 EBITDA Direct
So, Deepak, this first, like I mentioned, we are in the process of setting up our genomic lab, so there was a one-off consumption of around Rs. 1.5 Cr because we are validating the tests for our genomic lab. That was one major contribution by which our EBITDA was not as strong. T
Clarified the specific, non-recurring reasons for Q4 EBITDA decline, providing transparency on margin fluctuations.
Asked by Deepak Malik
FY26 EBITDA margin expansion despite new center additions Direct
We expect it to close around 36% should be the lowest EBITDA that we achieve in this year. Yes. (in response to 200 bps margin expansion from 33.8% despite new centers)
Confirmed management's confidence in margin improvement for FY26, indicating operating leverage and mature center performance will offset initial losses from new centers.
Asked by Deepak Malik
Unlock risks & concerns, Q1 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 7 risks, concerns & management red flags
- 5 watchlist triggers for Q1 FY26
- +5 more guidance targets & verbatim management quotes
- +5 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





